Hereditary angioedema – Pipeline Insight, 2020
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Hereditary angioedema – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Hereditary angioedema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Hereditary angioedema: Overview
Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction of the airway. About one-third of people with this condition develop a non-itchy rash called erythema marginatum during an attack.
Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty. On average, untreated individuals have an attack every 1 to 2 weeks, and most episodes last for about 3 to 4 days. The frequency and duration of attacks vary greatly among people with hereditary angioedema, even among people in the same family.
There are three types of hereditary angioedema, called types I, II, and III, which can be distinguished by their underlying causes and levels of a protein called C1 inhibitor in the blood. The different types have similar signs and symptoms. Type III was originally thought to occur only in women, b.
Symptoms
The symptoms of Hereditary angioedema includes:
It is important to note that MOST cases of angioedema or swelling are NOT HAE or C1 Inhibitor Deficiency. Laboratory analysis of blood samples, or genetic samples, are required to establish an HAE diagnosis.
There are three specific blood tests used to confirm Hereditary Angioedema Type I or II.
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition
This segment of the Hereditary angioedema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hereditary angioedema Emerging Drugs
Further product details are provided in the report
Hereditary angioedema: Therapeutic Assessment
This segment of the report provides insights about the different Hereditary angioedema drugs segregated based on following parameters that define the scope of the report, such as:
Hereditary angioedema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hereditary angioedema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hereditary angioedema drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Hereditary angioedema – Pipeline Insight, 2020,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Hereditary angioedema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hereditary angioedema: Overview
Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction of the airway. About one-third of people with this condition develop a non-itchy rash called erythema marginatum during an attack.
Symptoms of hereditary angioedema typically begin in childhood and worsen during puberty. On average, untreated individuals have an attack every 1 to 2 weeks, and most episodes last for about 3 to 4 days. The frequency and duration of attacks vary greatly among people with hereditary angioedema, even among people in the same family.
There are three types of hereditary angioedema, called types I, II, and III, which can be distinguished by their underlying causes and levels of a protein called C1 inhibitor in the blood. The different types have similar signs and symptoms. Type III was originally thought to occur only in women, b.
Symptoms
The symptoms of Hereditary angioedema includes:
- Angioedema
- Abdominal pain
- Ascites
- Facial edema
- Intestinal edema
It is important to note that MOST cases of angioedema or swelling are NOT HAE or C1 Inhibitor Deficiency. Laboratory analysis of blood samples, or genetic samples, are required to establish an HAE diagnosis.
There are three specific blood tests used to confirm Hereditary Angioedema Type I or II.
- C1-inhibitor quantitative (antigenic)
- C1-inhibitor functional
- C4
The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition
- C1 esterase inhibitor (human) (Brand name: Cinryze) - Manufactured by ViroPharma Biologics, Inc. was approved June 2018 for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).
- Icatibant (Brand name: Firazyr) - Manufactured by Shire Orphan Therapies is FDA-approved indication for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
- Ecallantide (Brand name: Kalbitor) - Manufactured by Dyax Corp is FDA-approved indication for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older
This segment of the Hereditary angioedema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hereditary angioedema Emerging Drugs
- BCX7353: BioCryst Pharmaceuticals
- KVD900: KalVista Pharmaceuticals
- PHA121: Pharvaris
- BMN 331: BioMarin Pharmaceutical
Further product details are provided in the report
Hereditary angioedema: Therapeutic Assessment
This segment of the report provides insights about the different Hereditary angioedema drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hereditary angioedema
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Hereditary angioedema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hereditary angioedema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hereditary angioedema drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hereditary angioedema R&D. The therapies under development are focused on novel approaches to treat/improve Hereditary angioedema.
- In February 2020, BioCryst Pharmaceuticals announced that the US Food and Drug Administration (FDA) accepted and filed its new drug application (NDA) for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.
- KVD900 received Fast Track designation from the US FDA, supporting the Company’s belief in the high level of unmet need in HAE and providing a potentially expedited path to drug approval.
- BioMarin expect to complete preclinical work with BMN 331 in the year 2020 and in anticipation of a possible clinical trial in early 2021.
- Hereditary angioedema Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hereditary angioedema drugs?
- How many Hereditary angioedema drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hereditary angioedema?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hereditary angioedema therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hereditary angioedema and their status?
- What are the key designations that have been granted to the emerging drugs?
- BioCryst Pharmaceuticals
- KalVista Pharmaceuticals
- Pharvaris
- BioMarin Pharmaceutical
- Ionis Pharmaceuticals, Inc.
- Pharming Technologies B.V.
- Adverum Biotechnologies
- Intellia Therapeutics
- Pharming Group NV
- BCX7353
- KVD900
- PHA121
- BMN 331
- IONIS-PKK-LRx
- rhC1INH
- ADVM 053
- Research Programme: hereditary angioedema therapeutics
- Conestat alfa
Introduction
Executive Summary
Hereditary angioedema: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hereditary angioedema – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Hereditary angioedema companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hereditary angioedema Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III and NDA)
Comparative Analysis
BCX7353: BioCryst Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
KVD900: KalVista Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PHA121: Pharvaris
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BMN 331: BioMarin Pharmaceutical
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Hereditary angioedema Key Companies
Hereditary angioedema Key Products
Hereditary angioedema- Unmet Needs
Hereditary angioedema- Market Drivers and Barriers
Hereditary angioedema- Future Perspectives and Conclusion
Hereditary angioedema Analyst Views
Hereditary angioedema Key Companies
Appendix
Executive Summary
Hereditary angioedema: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Hereditary angioedema – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Hereditary angioedema companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Hereditary angioedema Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III and NDA)
Comparative Analysis
BCX7353: BioCryst Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
KVD900: KalVista Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
PHA121: Pharvaris
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BMN 331: BioMarin Pharmaceutical
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Hereditary angioedema Key Companies
Hereditary angioedema Key Products
Hereditary angioedema- Unmet Needs
Hereditary angioedema- Market Drivers and Barriers
Hereditary angioedema- Future Perspectives and Conclusion
Hereditary angioedema Analyst Views
Hereditary angioedema Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Hereditary angioedema
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Hereditary angioedema
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Hereditary angioedema
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Hereditary angioedema
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
